

Secondary Trading Notice Pursuant to Section 708A(5)(e) of the Corporations Act

Neurotech International Limited (ASX: NTI) ("NTI" or "the Company"), gives this notice pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) ("Corporations Act").

The Company advises that it has issued ordinary fully paid shares in the capital of the Company, per the Appendices 2A released on 17 and 18 September 2024 ("Shares"). The Shares were issued without disclosure to investors under Part 6D.2 of the Act.

The Company, as at the date of this notice, has complied with:

- (a) the provisions of Chapter 2M of the Act as they apply to the Company; and
- (b) section 674 of the Corporations Act.

As at the date of this notice, other than disclosed below, there is no information to be disclosed which is excluded information (as defined in section 708A(7) of the Corporations Act) that is reasonable for investors and their professional advisers to expect to find in a disclosure document.

NTI refers to the biotechnology licence deed for NTI's exclusive worldwide licence to use certain cannabis strains for medicinal use in treating neurological disorders executed with Dolce Cann Global Pty Ltd ("**Dolce**") dated 29 September 2020 (**Licence Deed**) (refer ASX announcements dated 3 July 2020, 30 September 2020 and 2 March 2021).

NTI received correspondence from Dolce's solicitors dated 4 September 2024 alleging that NTI has breached certain provisions of the Licence Deed. If the alleged breaches are not remedied, Dolce has indicated that it may wish to terminate the Licence Deed and pursue potential remedies.

The Board has considered the allegations raised in the correspondence and unequivocally refutes the claims as baseless. As such, NTI intends to respond to the correspondence shortly refuting the alleged breaches. Neurotech directly owns a portfolio of patent applications associated with the composition of different cannabinoids, their use in neurological disorders and modification of proteomic pathways in humans.

Authority

This announcement has been authorised for release by the Board of Neurotech International Limited.

Investors:

Dr Thomas Duthy
Executive Director
td@neurotechinternational.com
+61 (0)402 493 727

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders. Neurotech has completed a Phase I/II clinical trial in Autism Spectrum Disorder (ASD), which demonstrated excellent safety and efficacy results at 28 days, 20 weeks and 52 weeks of treatment with NTI164. The Company has commenced a Phase II/III randomised, double-blind, placebo-controlled clinical trial in ASD, and completed a Phase I/II trial in Rett Syndrome and in Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS. In addition, Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.